Aptorum Group
Open
$0.84
Prev. Close
$0.84
High
$0.84
Low
$0.84
Market Snapshot
$6.02M
-2.64
$1.29M
1
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
Aptorum Group's industry faces advancements as APM Terminals Los Angeles enhances its fleet with 40 electric tractors, marking a significant step toward electrification in logistics.
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The firm's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
Recently from Cashu
Aptorum Group Advances SAct-1 Antibiotic to Combat Drug-Resistant Infections
Aptorum Group Advances in Antimicrobial Drug Development Aptorum Group, a biopharmaceutical company focused on developing innovative therapeutics, makes significant strides in the realm of antimicrobi…
Aptorum Group Experiences Volatile Trading Amidst Significant Stock Fluctuations
Aptorum Group Faces Volatile Trading Amid Business Developments Aptorum Group Limited is currently navigating a highly volatile trading environment, marked by significant fluctuations in its stock pri…
Aptorum Group Advances Drug Development for Antibiotics and Metabolic Disorders
Aptorum Group Advances in Drug Development Initiatives Aptorum Group Limited focuses on the development of innovative pharmaceutical products. Recently, the company has garnered attention due to its c…
Aptorum Group Advances SACT-1: A Novel Antibiotic Against Resistant Infections
Aptorum Group Pioneers Innovative Antibiotic Development Aptorum Group, a biopharmaceutical company focused on identifying and developing novel therapeutics, makes significant strides in the field of…